Positions

Overview

  • Dr. Acosta Lara received her initial medical training at Universidad Autónoma de Tamaulipas with her internship and residency completed at University of Texas Medical Branch. Dr. Acosta Lara served as Chief Resident at the University of Texas Medical Branch after completing her residency training. Dr. Acosta Lara began a clinical and research fellowship at UAB in 2013. Following her fellowship, she joined the UAB faculty in July 2016 as Assistant Professor

    • Selected Publications

    Research Overview

  • Dr. Acosta Lara's research and clinical interests relate to interstitial lung diseases with a particular interest those related to connective tissue diseases. Dr. Acosta has published and presented work on interstitial lung diseases, sarcoidosis and oxidative stress.

    • Principal Investigator On

    Investigator On

  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by Memorial Sloan-Kettering Cancer Center
  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by NHS GREATER GLASGOW AND CLYDE
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • Determinants of Efficacy and Toxicities among Patients with Lymphoid and Histiocytic Disorders  awarded by Memorial Sloan-Kettering Cancer Center
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh The
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by MALLINCKRODT ARD, INC
  • Private Grant  awarded by BIOGEN MA INC
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD
  • Private Grant  awarded by GENKYOTEX SA
  • Private Grant  awarded by PRIME EDUCATION LLC
  • Private Grant  awarded by ATYR PHARMA, INC.
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by BELLEROPHON PULSE TECHNOLOGIES LLC
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PURE TECH HEALTH LLC
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by CSL BEHRING, LLC
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by HORIZON THERAPEUTICS
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by KINEVANT SCIENCES INC
  • Private Grant  awarded by KINEVANT SCIENCES INC
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by ATYR PHARMA, INC.
  • Private Grant  awarded by PURETECH LYT 100, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh The

    • Education And Training

  • University of Texas Medical Branch at Galveston, Residency
  • University of Alabama at Birmingham Pulmonary, Allergy, and Critical Care Medicine, Postdoctoral Fellowship
  • Doctor of Medicine, Autonomous University of Tamaulipas 2006

    • Full Name

  • Maria Acosta Lara